# US 2013/0157988 A1 · Substituted androst-4-ene diones

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157988 A1
- Document ID: US20130157988A1
- Status: Published application
- Kind: A1
- Application number: 13/635,924
- Filed: 2011-04-07
- Published: 2013-06-20
- Earliest claimed: 2010-04-08
- Assignees: Emory University; Hauptman-Woodward Medical Research Institute, Inc.; Research Foundation of the State of New York
- Inventors: Huw Davies; Debashis Ghosh; Daniel Morton
- Web page: https://patentgrep.com/patent/US20130157988A1

## CPC

- A61K 31/5685: having an oxo group in position 17, e.g. androsterone
- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 35/00: Antineoplastic agents
- C07J 1/0011: {substituted in position 17 by a keto group}
- C07J 41/0005: {the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton}
- C07J 75/00: Processes for the preparation of steroids in general
- C07J 51/00: Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
- C07J 53/001: {spiro-linked}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07J: STEROIDS (seco-steroids C07C)

## Abstract

The disclosure relates to novel C4 and C6 substituted androst-4-ene diones as well as andros-1,4-diene diones and derivatives thereof, their process of preparation, pharmaceutical compounds containing them, and the use of said compounds for the treatment of hormone-related disorders in mammals. This includes hormone-dependent cancers, particularly those caused by elevated levels of estrogen and its intermediates. These compounds can also be used in the treatment of other hormone-related disorders, including benign prostatic hyperplasia, cardiovascular disease, and neurodegenerative disorders.

## Claims

### Claim 1

A compound of Formula A
or salts, ester, or prodrug thereof, wherein
————— represents a bond either absent or present as a double bond and R″ is absent when the double bond is present or is H when the bond is absent;
Z′ is hydrogen or is OR′ and Z is hydrogen or is OR, wherein when Z′ is hydrogen, Z is OR and when Z is hydrogen Z′ is OR′;
R and R′ are independently selected from an alkyl, alkenyl, or alkynyl group optionally substituted with one or more substituents.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Formula A is Formula C
or pharmaceutically acceptable salts, ester, prodrugs or derivatives thereof, wherein
————— represents a bond either absent or present as a double bond and
R2 is selected from H, a straight chain or branched C1 to C8 alkyl group, an alkenyl group, an alkynyl group, an alkanoyl group and an aroyl group, any of which may be substituted or unsubstituted.

### Claim 3 (depends on 1)

A compound of claim 1, wherein R′ is an alkyl substituted with an optionally substituted aryl group.

### Claim 4 (depends on 1)

A compound of claim 1, wherein R′ is alkenyl or alkynyl optionally substituted with one or more substituents.

### Claim 5 (depends on 1)

A compound of claim 1, wherein the substituent is selected from OH, phenyl, benzyl, naphthyl, substituted aryl, or C1 to C8 alkyl group.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the substituent is selected from aryl, substituted aryl, heterocyclo, substituted heterocyclo, carbocyclo, substituted carbocyclo, or halo.

### Claim 7 (depends on 1)

The compound of claim 1, wherein the substituent is selected from alkoxy (optionally substituted), aryloxy (optionally substituted), alkylester (optionally substituted), arylester (optionally substituted), alkanoyl (optionally substituted), or aryol (optionally substituted).

### Claim 8 (depends on 1)

The compound of claim 1, selected from the list:
(6R,8R,9S,10R,13S,14S)-10,13-dimethyl-6-(pentyloxy)-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione;
(6R,8R,9S,10R,13S,14S)-10,13-dimethyl-6-((E)-pent-2-en-1-yloxy)-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione;
(6R,8R,9S,10R,13S,14S)-10,13-dimethyl-6-(((Z)-pent-2-en-1-yloxy)-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione;
(6R,8R,9S,10R,13S,14S)-6-(cinnamyloxy)-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione;
(6R,8R,9S,10R,13S,14S)-10,13-dimethyl-6-(3-phenylpropoxy)-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione;
(6R,8R,9S,10R,13S,14S)-10,13-dimethyl-6-((5-phenylpentyl)oxy)-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione;
(6R,8R,9S,10R,13S,14S)-10,13-dimethyl-6-(oct-2-yn-1-yloxy)-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione; and
(6R,8R,9S,10R,13S,14S)-10,13-dimethyl-6-(pent-2-yn-1-yloxy)-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

### Claim 10 (depends on 9)

A method of treating a hormone-related disorders comprising administering a pharmaceutical composition of claim 9 to a subject in need thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein the subject is diagnosed with, at risk of, or exhibiting symptoms of a hormone-related disorder.

### Claim 12 (depends on 10)

The method of claim 10, wherein the hormone related disorder is osteoporosis, endometriosis, breast cancer, benign breast cancer, uterine cancer, ovarian cancer, polycystic ovarian disease, prostate cancer, or benign prostatic hyperplasia (BPH).

### Claim 13 (depends on 10)

The method of claim 10, wherein the pharmaceutical composition is administered in combination with estrogen.

### Claim 14 (depends on 1)

Use of a compound of claim 1, in the production of a medicament for the treatment of a hormone related disorder.

### Claim 15 (depends on 1)

A process for producing a compound of claim 1, comprising mixing (8R,9S,10R,13S,14S)-4-diazo-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(4H)-dione, an alcohol (R′—OH), and a metal catalyst under conditions such that a compound of Formula A is formed.

### Claim 16 (depends on 15)

The process of claim 15, wherein metal catalyst is silver catalyst or a of dirhodium(II) catalyst.
